Alembic Pharmaceuticals share news and announcements
NSE: APLLTDBSE: 533573Pharmaceuticals & BiotechnologySmall Cap
Last close ₹760.10down ₹21.20 (2.71%)BSE ₹758.75
Share price at the NSE close on 23 Oct 2026. Previous close ₹781.30.
52-week range of traded prices to 23 Oct 2026
₹635.80Low, 23 Mar 2026₹998.00High, 4 Nov 2025
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹14,941 Cr430th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 4 Aug 2026
- 21.6
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 15 May 2026
- 2.6
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 1.58%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 4 Aug 2026
- 12.7%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 4 Aug 2026
- 11.8%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 15 May 2026
- 0.24
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 1,20,84752.2% delivered
Alembic Pharmaceuticals board meetings
105 filed, newest first. Page 2 of 3.
Apr 2020
Feb 2020
25 Feb · Board meeting
Jan 2020
22 Jan · Board meeting
Oct 2019
24 Oct · Board meeting
Jul 2019
29 Jul · Board meeting
Jun 2019
12 Jun · Board meeting
Apr 2019
Mar 2019
Jan 2019
22 Jan · Board meeting
Dec 2018
6 Dec · Board meeting
3 Dec · Board meeting
Oct 2018
Sep 2018
10 Sep · Board meeting
Jul 2018
27 Jul · Board meeting
May 2018
16 May · Board meeting
Jan 2018
Nov 2017
7 Nov · Board meeting
Oct 2017
Jul 2017
Apr 2017
Jan 2017
Oct 2016
Jul 2016
Apr 2016
27 Apr · Board meeting
Jan 2016
7 Jan · Board meeting
To consider Unaudited Financial Results of the Company for the quarter ended on December 31, 2015.
Oct 2015
Jul 2015
Apr 2015
9 Apr · Board meeting
Inter alia, to transact following business: (1). To consider and approve Audited Financial Results of the Company for the Financial year ended March 31, 2015 (2). To consider and recommend dividend on Equity Shares, if any, for the Financial Year ended March 31, 2015.
Jan 2015
Sep 2014
24 Sep · Board meeting
Inter alia to consider and approve the Unaudited Financial Results of the Company for the Quarter ended September 30, 2014. The trading window shall remain closed from October 17, 2014 to October 21, 2014 for the above purpose.
Jul 2014
28 Jul · Board meeting
Board of Directors of the company at its meeting held on July 28, 2014 has inter alia taken following decisions : (1) Designation of Mr. R. K. Baheti, Director-Finance & Company Secretary of the Company as Director-Finance & Chief Financial Officer of the Company w.e.f. July 28, 2014 (2) Designation of Mr. Ajay Kumar Desai, Associate Vice President-Finance of the Company as Associate Vice President-Finance & Company Secretary and Compliance Officer of the Company w.e.f. July 28, 2014 .
Jun 2014
20 Jun · Board meeting
Inter alia, to consider and approve the Unaudited Financial Results of the Company for the Quarter ended June 30, 2014.Further, the trading window shall remain closed from July 25, 2014 to July 29, 2014 for the above purpose.
Apr 2014
Dec 2013
Oct 2013
9 Oct · Board meeting
Company had informed the Exchange that a meeting of the Board of Directors of the Company will be held on October 30, 2013 inter alia, to consider and approve the Unaudited Financial Results of the Company for the Quarter ended on September 30, 2013. The Company has now informed the Exchange that the aforesaid Board Meeting has been rescheduled and will now be held on October 25, 2013.Not held on this date
1 Oct · Board meeting
Inter alia, to consider and approve the Unaudited Financial Results of the Company for the Quarter ended on September 30, 2013.
Jul 2013
9 Jul · Board meeting
Inter alia to consider and approve the Unaudited Financial Results of the Company for the Quarter ended June 30, 2013.
Mar 2013
15 Mar · Board meeting
Inter alia, to transact following business : (1) To consider and approve Audited Financial statements of the Company for the Financial year ended March 31, 2013; (2) To consider and recommend dividend for the Financial Year ended March 31, 2013.
Dec 2012
18 Dec · Board meeting
Inter alia, to consider and approve the Un-audited Financial Results of the Company for the quarter ended on December 31, 2012.